Researchers Receive Grants from NCCN Oncology Research Program Funded Through GlaxoSmithKline

The NCCN Oncology Research Program received $4 million in research funding from GlaxoSmithKline to support research at NCCN Member Institutions in order to evaluate the effectiveness of ofatumumab (Arzerra®, GlaxoSmithKline) in hematologic malignancies and pazopanib (Votrient™, GlaxoSmithKline) in the treatment of solid tumors. FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) recently awarded...
Source: National Comprehensive Cancer Network Oncology Research Program - Category: Cancer & Oncology Source Type: news